SCHEMBL26429710

SCHEMBL26429710

COC(=O)CC1Oc2ccccc2C1C(C)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.38
TSHR P16473 2/20 0.38
EGFR P00533 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 4/20 0.35
CYP3A4 P08684 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CYP1A2 P05177 1/20 0.34
CHRM2 P08172 1/20 0.34
CYP2D6 P10635 1/20 0.34
CHRM1 P11229 1/20 0.34
NFKB1 P19838 1/20 0.34
KCNH2 Q12809 1/20 0.34
PRMT1 Q99873 1/20 0.34
KCNA5 P22460 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22877348 0.88 TSHR (0.39) L3MBTL1TSHREGFRSMN1; SMN2ALDH1A1
SCHEMBL22877184 0.80 POLB (0.44) L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A
SCHEMBL26429627 0.79 POLB (0.40) EGFRSMN1; SMN2ALDH1A1POLBMAPT
SCHEMBL26429715 0.79 POLB (0.40) EGFRSMN1; SMN2ALDH1A1POLBMAPT
SCHEMBL26705254 0.77 POLB (0.42) L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A
SCHEMBL26429458 0.77 ALDH1A1 (0.40) L3MBTL1TSHRSMN1; SMN2ALDH1A1POLB
SCHEMBL26429687 0.70 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1POLBKMT2AMAPT
SCHEMBL22877375 0.70 POLB (0.40) EGFRALDH1A1POLBCYP2D6LMNA
SCHEMBL22877204 0.70 POLB (0.40) EGFRALDH1A1POLBCYP2D6LMNA
SCHEMBL26429691 0.69 LTB4R (0.41) L3MBTL1TSHRSMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639340-B2 Substituted chromanes, analogs thereof, and methods of use and synthesis NORTHWESTERN UNIVERSITY (US) 2023-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639340-B2 Substituted chromanes, analogs thereof, and methods of use and synthesis TYR, ME1, PNPO L3MBTL1 1006/4885TSHR 861/4885EGFR 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.